Novo Nordisk (NVO)
(Delayed Data from NYSE)
$126.85 USD
+1.06 (0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $126.90 +0.05 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
NVO 126.85 +1.06(0.84%)
Will NVO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Other News for NVO
ClearBridge Global Growth Strategy Q1 2024 Portfolio Manager Commentary
Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
AstraZeneca: Strong In A Weak Market
Interesting NVO Put And Call Options For June 7th
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years